LL-37

WHAT IT IS

LL-37 is a naturally occurring 37-amino-acid peptide that the human body produces from a larger precursor protein encoded by the CAMP gene. It is the only member of the cathelicidin family of antimicrobial peptides found in humans.

It is made by neutrophils, skin keratinocytes, epithelial cells and several other cell types, and it is released as part of the body's first-line, innate immune response, distinct from the slower antibody-based adaptive immune system.

LL-37 itself is a naturally occurring human peptide, not a manufactured drug on the market. Synthetic versions and related formulations have been developed as investigational drug candidates, and those are a separate regulatory matter from the peptide's natural biological role.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published research on LL-37 spans basic human biology and early-stage drug development, including:

• Direct antimicrobial activity against bacteria, some fungi and certain enveloped viruses in laboratory settings
• Wound healing and tissue repair signaling, including a completed phase II trial of a synthetic LL-37 formulation in venous leg ulcers
• Immune cell recruitment and modulation of inflammatory responses
• Its contested, dual role in inflammatory skin conditions such as psoriasis and rosacea, where LL-37 is implicated in driving inflammation rather than only defending against it
• Interactions with the skin microbiome and barrier function
• Structural and synthetic analog research aimed at improving stability and reducing toxicity for potential drug development

PROPOSED BIOLOGICAL MECHANISMS

LL-37 is generally described as disrupting microbial cell membranes directly, a mechanism distinct from how most conventional antibiotics work, which is part of why it draws interest as researchers look for new ways to address resistant organisms.

Beyond direct antimicrobial killing, LL-37 acts as a signaling molecule, activating immune cells and influencing cytokine release, which places it at the intersection of infection defense and inflammation regulation.

In skin conditions like psoriasis, elevated LL-37 has been shown in human tissue and cell studies to bind self DNA and RNA released from damaged cells, activating inflammatory pathways that are thought to contribute to disease flares rather than resolve them.

This dual identity, protective in some contexts and pro-inflammatory in others, is one of the more actively debated aspects of LL-37 biology and is not fully resolved.

AREAS OF RESEARCH INTEREST

• Whether synthetic LL-37 or engineered analogs can be developed into safe, effective antimicrobial or wound-healing drugs
• How to reduce the toxicity and inflammatory activation associated with higher concentrations of the native peptide
• Whether blocking excess LL-37 activity could help conditions like psoriasis and rosacea, an approach that would be the opposite of using LL-37 as a therapeutic
• How LL-37 levels and activity vary across healthy skin, chronic wounds and inflammatory skin disease

WHAT THE EVIDENCE CURRENTLY SUGGESTS

The underlying biology of LL-37 is well characterized. Its role in human innate immunity, wound-related signaling and inflammatory skin disease pathology is supported by a large body of laboratory and human tissue research.

As a therapeutic candidate, evidence is early-stage. A synthetic LL-37-based formulation completed a phase II trial for venous leg ulcers, but that is a preliminary clinical result, not an approved treatment, and larger, later-stage trials would be needed to establish efficacy and safety at the standard the FDA requires.

For inflammatory skin conditions, the research points toward LL-37 as part of the problem, not a solution, since elevated levels are associated with disease activity in psoriasis and rosacea. That distinction matters and separates it from antimicrobial peptide research more broadly.

FDA status: LL-37 is not FDA-approved as a drug for any indication. Synthetic material sold outside legitimate pharmaceutical or research channels carries additional, distinct safety and quality concerns that regulators have specifically flagged around unregulated compounded peptides.